Incyte Partners with Genesis to Develop and Commercialize Novel Small Molecules Using Genesis’ GEMS AI Platform
Shots:
- Incyte has partnered with Genesis to advance research, discovery, & development of novel small molecules using GEMS (Genesis Exploration of Molecular Space) AI platform, initially focusing on targets selected by Incyte
- As per the agreement, Incyte will gain exclusive rights to develop & commercialize products arising from this deal in exchange for $30M upfront, ~$295M/target in development, regulatory & commercial milestones, plus sales-based tiered royalties
- In addition, Genesis & Incyte have agreed to collaborate on 2 initial targets, with Incyte retaining the option to nominate an additional target for a predetermined fee
Ref: Incyte | Image: Incyte & Genesis
Related News:- Incyte Highlights the P-III (inMIND) Study Data of Monjuvi (Tafasitamab) to Treat R/R Follicular Lymphoma at ASH 2024
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
